Core Insights - Revvity, Inc. (RVTY) has announced a collaboration with Eli Lilly and Company to integrate Eli Lilly's TuneLab predictive models into the Revvity Signals platform, enhancing AI-driven drug discovery capabilities [1][8] - The partnership aims to address challenges in AI drug discovery by utilizing federated learning and secure knowledge sharing, allowing organizations to collaborate effectively [2][10] - Revvity's stock has seen a 2.7% increase since the announcement, with a 6.1% rise over the past six months, compared to the industry's 10.6% growth and the S&P 500's 14.1% increase [3] Company Developments - The collaboration reinforces RVTY's Signals Xynthetica as a key component of its AI-enabled drug discovery strategy, promoting innovation across the biotech sector [4] - Joint funding initiatives by Eli Lilly and Revvity for small- and mid-sized biotech firms aim to lower entry barriers and encourage broader adoption of the Signals ecosystem [4][10] - RVTY currently holds a market capitalization of $11.84 billion, indicating its significant presence in the market [6] Technology and Market Trends - The TuneLab models leverage advanced AI and machine learning, built on extensive research data from Eli Lilly and the biotech community, enhancing predictive accuracy through federated learning [9] - The Signals platform provides essential infrastructure for utilizing TuneLab models, facilitating data management and collaboration among research teams [11] - The AI in drug discovery market is projected to reach $7.62 billion by 2026, with a CAGR of 9.9% through 2035, driven by reduced drug discovery time and costs, and increased adoption post-COVID-19 [12] Strategic Acquisitions - Revvity has announced plans to acquire ACD/Labs, enhancing its Signals capabilities by integrating advanced analytical software for pharmaceutical and materials science applications [13]

Core Viewpoint - Revvity, Inc. is a life sciences and diagnostics company with a market cap of $11.1 billion, providing essential tools for genetic screening and infectious disease testing [1] Financial Performance - Analysts anticipate Revvity to report an adjusted earnings of $1.54 per share for the fourth quarter, reflecting an 8.5% increase from $1.42 per share in the same quarter last year [2] - For fiscal 2025, adjusted EPS is expected to be $4.91, slightly up from $4.90 in 2024, with a projected 8.2% annual increase to $5.31 per share in fiscal 2026 [3] Stock Performance - RVTY stock has decreased by 12.4% over the past 52 weeks, underperforming compared to the Healthcare Select Sector SPDR Fund's 13% increase and the S&P 500 Index's 16.9% gain [4] Growth and Profitability Challenges - Revvity has experienced weak underlying growth with constant-currency revenue growth averaging only 2% over the last two years, indicating soft demand [5] - Profitability has declined, with adjusted operating margin decreasing by over 9 percentage points in the past five years due to rising costs and limited operating leverage [5] - Financial performance has deteriorated, with both revenue and EPS declining annually over the past five years, leading to cautious investor sentiment [5]

Diamond Hill Capital, an investment management company, released its “Mid Cap Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Markets continued their rally in the third quarter, with US stocks gaining over 8% as measured by the Russell 3000 Index. Small-cap stocks experienced the strongest quarterly performance, rising by more than 12%, whereas large-cap stocks increased by about 8%, and mid-cap stocks saw a gain of 5%. The strategy underperformed the Russell Midca ...

Core Insights - Revvity, Inc. has launched Signals Xynthetica, an AI-augmented design platform aimed at enhancing molecular and materials discovery across scientific industries [2][8] - The platform operates as a Models-as-a-Service (MaaS) solution, integrating advanced in-silico design capabilities with real experimental data [2][4] - Early access to Signals Xynthetica is expected in the first half of 2026, with pre-registration already underway [3][8] Product Features - Signals Xynthetica addresses the disconnect between computational models and experimental workflows, aiming to unify de novo generation, property prediction, and multi-objective optimization [4] - The platform is designed to accelerate discovery while maintaining scientific rigor, adapting to new data and benchmarking against real-world results [4][5] - Revvity emphasizes that the initiative serves as an operational backbone for predictive science, aligning AI predictions with laboratory realities [5] Market Position and Trends - Following the announcement, RVTY shares have remained relatively flat, gaining 1.4% over the past six months compared to the industry’s 6.2% growth and the S&P 500's 15.3% increase [6] - The introduction of Signals Xynthetica is expected to enhance Revvity's prospects as demand for predictive tools integrated with empirical workflows grows [7] Strategic Vision - Revvity is evolving from a provider of discrete scientific tools to a platform-centric technology partner, leveraging AI and cloud delivery to accelerate discovery and standardize workflows [14] - The acquisition of ACD/Labs is expected to strengthen Revvity's strategy by incorporating specialized analytical and molecular design tools into the Signals ecosystem [15]

Core Insights - OpenAI, Anthropic, and Google are actively seeking various professional data to train AI models, focusing on obtaining data set authorizations in fields like genomics [1][2] Group 1: Company Engagements - OpenAI has engaged with multiple companies, including life sciences diagnostic supplier Revvity and accounting software provider Xero, to explore data authorization and collaboration opportunities [1][2] - Anthropic, DeepMind, and Google's independent company focused on AI drug development, Isomorphic Labs, are also in discussions with several early-stage biotech startups regarding data authorization or collaboration [1][2]

Revvity, Inc. (RVTY), headquartered in Waltham, Massachusetts, is a leading provider of health sciences solutions, technologies, and diagnostic services. Valued at $11.4 billion by market cap, the company focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, diagnosis, informatics, and other areas. Companies worth $10 billion or more are generally described as “large-cap stocks,” and RVTY perfectly fits that description, with its market ca ...

Question-and-Answer SessionI guess maybe we can start just high level. You guys just reported last month. There's been a lot of noise in tools land on the positive side, which is nice in terms of some of the pharma conversation. Maybe just give us a lay of the land in terms of how you're feeling at the moment coming out of 3Q. Again, what the right way to think about some of the pharma news is and then what it might mean to you?Prahlad SinghCEO, President & Director Sure, Patrick. Thanks for the invite. It' ...

Financial Data and Key Metrics Changes - The company experienced an uplift of approximately $60 million from Q3 to Q4, driven by three primary factors including a significant increase in the Genomics England contract from $2 million in Q3 to $7 million in Q4 [1][2][52] - The foreign exchange (FX) impact was less favorable than predicted, resulting in a drag of $5-$7 million on absolute dollar amounts, which is 1% less than expected [3][52] Business Line Data and Key Metrics Changes - The life sciences instrumentation side showed continued good activity, with trends remaining stable compared to previous months [2] - The reagents business, particularly from BioLegend, faced modest impacts from government shutdowns, while the pharma biotech sector showed signs of recovery [5][10] - The software segment has grown over 20% each quarter this year, significantly exceeding initial guidance of 10% [20][21] Market Data and Key Metrics Changes - The U.S. market for immunodiagnostics has grown from 5% to 15-20% of total EUROIMMUN revenue since acquisition, with expectations to reach 40-45% as more assays are introduced [38][39] - The China market remains crucial, with expectations for diagnostics to stabilize around 5-6% of company revenue, while life sciences in China is projected to be around 10-12% [44][45] Company Strategy and Development Direction - The company aims to leverage AI and machine learning across its product lines, focusing on enhancing drug discovery and development processes [22][35] - Strategic acquisitions will continue, with a focus on sensible and financially sound opportunities, as demonstrated by the recent acquisition of ACD/Labs [58] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the recovery in the pharma biotech sector, indicating that increased M&A activity would signal normalization in the market [7][8][16] - The company anticipates stable growth in 2026, projecting 2-3% growth with 28% margins, accounting for various market dynamics [56][57] Other Important Information - The company has been proactive in addressing challenges in the China market, focusing on innovation and local competition strategies [43][44] - The newborn screening segment has shown growth driven by geographic expansion and partnerships with local governments [48][49] Q&A Session Summary Question: Can you discuss the life sciences diagnostics and the impact of government shutdowns? - The reagents business saw modest impacts from shutdowns, but the pharma biotech sector is recovering, indicating a return to normalcy [5][10] Question: What are the expectations for the software business moving forward? - The software segment is expected to continue its strong growth trajectory, with a focus on annualized portfolio value as a key metric [27][29] Question: How does the company view the China diagnostics market? - The company acknowledges the challenges in China but remains focused on innovation and local market strategies to stabilize and grow [42][44]

Financial Data and Key Metrics Changes - The company reported an uplift of approximately $60 million from Q3 to Q4, driven by three primary factors: the Genomics England contract, seasonal uplift in life sciences instrumentation, and strong performance in immunodiagnostics outside of China [2][4][54] - The foreign exchange (FX) impact was less favorable than anticipated, resulting in a $5-$7 million drag on absolute dollar amounts, which is about 1% less than expected [4] Business Line Data and Key Metrics Changes - The diagnostics segment saw contributions from the Genomics England contract, increasing from $2 million in Q3 to $7 million in Q4 [2] - The life sciences instrumentation side continued to show good activity, with seasonal uplift expected rather than a significant budget flush [3][14] - The reagents business, particularly from BioLegend, faced modest impacts from government shutdowns, but the pharma biotech sector showed signs of recovery [6][10] Market Data and Key Metrics Changes - The U.S. market for immunodiagnostics has grown from 5% to 15-20% of total EUROIMMUN revenue since acquisition, with expectations to reach 40-45% as more assays are introduced [39] - The China market is projected to stabilize, with diagnostics expected to contribute 5-6% of total revenue, while life sciences in China is anticipated to be around 10-12% [46][47] Company Strategy and Development Direction - The company aims to innovate in the Chinese market by operating as a local entity and focusing on reproductive health and newborn screening [45] - There is a strong emphasis on leveraging AI and machine learning across product lines, particularly in drug discovery and development, which is expected to drive future growth [23][38] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the recovery in the pharma biotech sector, indicating that increased activity and discussions with customers are signs of normalization [17][19] - The company is confident in its 2026 growth projections of 2-3% and 28% margins, having accounted for market stability and the impact of calendarization on China [60][61] Other Important Information - The software segment has outperformed expectations, growing over 20% each quarter, driven by diligent investment and customer engagement [21][22] - The company remains open to acquisitions but is focused on strategic and sensible opportunities rather than paying high multiples [61] Q&A Session Summary Question: Can you discuss the life sciences diagnostics and the impact of the government shutdown? - The reagents business, particularly from BioLegend, was modestly impacted by the shutdown, but the pharma biotech sector continues to perform well, indicating a return to normalcy [6][10] Question: How quickly can biotech recover and what are the signs? - Recovery in biotech is linked to market stability and increased M&A activity, which are expected to normalize over the next couple of quarters [8][9] Question: What is the outlook for the China diagnostics market? - The company anticipates that China diagnostics will stabilize, contributing around 5-6% of total revenue, with a focus on localizing operations and obtaining faster approvals [46][47] Question: How does the company view its software growth trajectory? - The software business is expected to continue growing, with a focus on annualized portfolio value rather than just organic growth metrics [29][30] Question: What are the capital allocation priorities moving forward? - The company remains acquisitive but is focused on strategic acquisitions that align with its core business, while also considering share repurchases as a priority [61]

Financial Data and Key Metrics Changes - The company experienced an uplift of approximately $60 million from Q3 to Q4, driven by three primary factors including the Genomics England contract which contributed around $7 million in Q4 compared to $2 million in Q3 [1][2] - The foreign exchange (FX) impact was a drag of $5-$7 million, which is 1% less than previously predicted, affecting absolute dollar amounts but having minimal impact on growth and earnings per share (EPS) [3] Business Line Data and Key Metrics Changes - The life sciences instrumentation side has shown good activity, with seasonal uplift expected rather than a significant budget flush [2][12] - The reagents business, particularly from BioLegend, faced modest impacts from government shutdowns, but the pharma biotech sector has shown signs of recovery [5][8] - The software segment has grown over 20% each quarter, significantly exceeding guidance, driven by diligent investment and customer engagement [19][21] Market Data and Key Metrics Changes - The U.S. market for EUROIMMUN has increased from 5% to 15-20% of total revenue since acquisition, with expectations to reach 40-45% as more assays are introduced [36] - The China diagnostics market is projected to stabilize, with expectations of it contributing 5-6% to total revenue, while autoimmune testing is anticipated to grow significantly [43][44] Company Strategy and Development Direction - The company is focusing on leveraging AI and machine learning in drug discovery and development, positioning itself as a critical player in the future of pharmaceutical research [22][31] - Strategic acquisitions will continue, with a focus on sensible and financially sound opportunities, as demonstrated by the recent acquisition of ACD/Labs [57] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the recovery in the pharma biotech sector, indicating that increased discussions and activity are signs of normalization [15][16] - The company is confident in its 2026 growth projections of 2-3% and 28% margins, accounting for stable market conditions and the impact of calendarization on China [54][56] Other Important Information - The company has been actively integrating AI across its product lines and internal operations, enhancing productivity and efficiency [34][35] - The newborn screening market has shown growth due to geographic expansion and the introduction of new assays, with partnerships driving further opportunities [46][48] Q&A Session Summary Question: Can you discuss the impact of the government shutdown on the reagents business? - The reagents business, particularly from BioLegend, experienced a modest impact from the shutdown, but the pharma biotech sector has continued to perform well [5][8] Question: What are the expectations for the software business moving into 2026? - The software business is expected to continue performing well, with a focus on annualized portfolio value (APV) rather than just organic growth [27][28] Question: How does the company view the China diagnostics market going forward? - The company anticipates that the China diagnostics market will stabilize, contributing around 5-6% to total revenue, with a focus on localizing operations and obtaining faster approvals [43][44]